Genetically modified FVIII-expressing autologous bone marrow-derived mesenchymal stromal cells (BMSCs) could cure haemophilia A. However, culture-expanded BMSCs engraft poorly in extramedullary sites. Here, we compared the intramedullary cavity, skeletal muscle, subcutaneous tissue and systemic circulation as tissue microenvironments that could support durable engraftment of FVIII-secreting BMSC in vivo. A zinc finger nuclease integrated human FVIII transgene into PPP1R12C (intron 1) of culture-expanded primary canine BMSCs. FVIII-secretory capacity of implanted BMSCs in each dog was expressed as an individualized therapy index (number of viable BMSCs implanted 9 FVIII activity secreted/million BMSCs/ 24 hours). Plasma samples before and after implantation were assayed for transgenic FVIII protein using an anti-human FVIII antibody having negligible cross-reactivity with canine FVIII. Plasma transgenic FVIII persisted for at least 48 weeks after implantation in the intramedullary cavity. Transgenic FVIII protein levels were low after intramuscular implantation and undetectable after both intravenous infusion and subcutaneous implantation. All plasma samples were negative for anti-human FVIII antibodies. Plasma concentrations and durability of transgenic FVIII secretion showed no correlation with the therapy index. Thus, the implantation site microenvironment is crucial. The intramedullary microenvironment, but not extramedullary tissues, supported durable engraftment of genetically modified autologous FVIIIsecreting BMSCs.
However, culture-expanded BMSCs engraft poorly in vivo.
BMSCs are intravenously infused in well over half of currently registered clinical trials. This is known to induce complement-mediated BMSC destruction which may partly explain equivocal results from hundreds of BMSC clinical trials. 6 The role of cell-specific tissue niches has not been adequately investigated as a factor that determines survival and engraftment of implanted BMSC. 7 We hypothesized that the microenvironment of the intramedullary bone marrow cavity would be more favourable than other tissue sites for FVIIIsecreting BMSC engraftment. Indeed, culture-expanded human BMSCs engrafted and differentiated after intramedullary transplantation in NOD/SCID mice. 8 Here we compare plasma FVIII levels after intramedullary, intramuscular, intravenous and subcutaneous implan- Figure 1D ). 
| In vivo implantation

| Plasma FVIII and anti-FVIII antibody assays
Citrated venous blood was drawn 3 weeks before cell implantation, immediately before implantation and thereafter at weekly intervals for 4 weeks, followed by monthly intervals. Plasma obtained by centrifugation (15 minutes at 1500 g; room temperature) was stored at À80°C until analysis.
Plasma samples were analysed for human FVIII protein using an antibody with negligible cross-reactivity against canine FVIII (VisuLize TM FVIII antigen ELISA kit; Affinity Biologicals, Canada). All plasma samples were also tested for anti-FVIII antibodies. 11 FVIII activity in conditioned media of ZFN-modified BMSCs was quantified as previously described. 10 
| RESULTS AND DISCUSSION
Bone marrow-derived mesenchymal stromal cells (BMSC) immunophenotypes in this study resembled that of human MSCs and previously described canine BMSCs 12,13 ( Figure 1E ). Table 1 summarizes characteristics of in vitro BMSC expansion. The theoretical number of BMSCs expandable from all 10 mL of bone marrow aspirate from each dog was 1.5-to 20.2-fold greater than the number of BMSCs used for FVIII transgene integration. These differences in canine BMSC yield and ex vivo expansion potential are similar to inter-donor differences for human BMSC.
FVIII activity was assayed in 24-hour conditioned media of an aliquot of ZFN-treated BMSCs taken on the day of implantation ( 24 h after electroporation with a GFP-expressing plasmid. E, A representative profile of positive and negative markers of mesenchymal stromal cells present in early passage BMSCs in this study analysed by flow cytometry as previously described. 4 Broken lines denote the corresponding isotype control. Bone marrow was obtained by aspiration through the trochanteric fossa of the femur. Summary of mesenchymal stromal cell markers of BMSCs of all dogs in our study compared with data of Takemitsu et al of primary bone marrow-derived mesenchymal stem cells of 4 beagle dogs. 13 The histogram subtraction method was used to calculate the mean percentage AE standard deviation of cells positive for each surface protein. 15 All antibodies used for immunophenotyping were reactive against the cognate canine protein except anti-CD105 antibody whose reactivity against canine CD105 was not specified by the manufacturer. Autologous cell therapy could be advantageous over factor replacement which is costly and requires frequent venous access.
Cryopreserved BMSCs remain functional and can be used for repeat treatments. However, several improvements are essential for genetically modified autologous BMSC therapy to be clinically feasible. 
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